praveen
08-09-2008, 08:05 AM
A leading brokerage house strongly recommends Surya Pharma for long-term with a target of Rs.150. SPL is likely to post an EPS of Rs.45 in FY09.
Some analysts are bullish on Core Projects. The shares are being bought by circles close to the management and expect the share price to cross the Rs.350 mark in the short-term
Some analysts are bullish on Core Projects. The shares are being bought by circles close to the management and expect the share price to cross the Rs.350 mark in the short-term